Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Nyxoah ( (NYXH) ) just unveiled an announcement.
On September 5, 2025, Nyxoah SA announced it received a transparency notification from Cochlear Limited and Cochlear Investments Pty Ltd regarding a passive crossing of a voting rights threshold. As of August 29, 2025, Cochlear Investments Pty Ltd holds 5,631,319 voting rights, representing 14.999% of Nyxoah’s total voting rights, slightly below the 15% threshold. This change reflects a passive decrease in Cochlear’s holdings, impacting Nyxoah’s shareholder structure and potentially influencing its market dynamics.
The most recent analyst rating on (NYXH) stock is a Buy with a EUR12.00 price target. To see the full list of analyst forecasts on Nyxoah stock, see the NYXH Stock Forecast page.
More about Nyxoah
Nyxoah SA operates in the medical technology industry, focusing on the development and commercialization of innovative solutions for the treatment of sleep-disordered breathing conditions. The company is known for its implantable neurostimulation devices, which target obstructive sleep apnea, a condition affecting millions globally.
YTD Price Performance: -40.44%
Average Trading Volume: 58,347
Current Market Cap: €184.2M
See more data about NYXH stock on TipRanks’ Stock Analysis page.